Pain

OPERA

(_Optimizing _Patient _Experience and _Response to Topical _Analgesics)

OPERA is our closed, PAIN Study. This IRB-approved clinical observational study focused on reducing pain with topical/transdermal analgesics for patients with chronic neuropathic or musculoskeletal pain.

Key Interim Results

27.5% reduction in opioid use and over 50% reductions in over-the-counter and anti-inflammatory medications while using topical/transdermal analgesics
Reductions in patient-reported pain severity and pain symptoms/complaints
Less pain interference with general activity, mood, sleep, relations with other people and life enjoyment.
The majority of patients enrolled preferred the topical/transdermal analgesics over oral medication, and 92% were satisfied with the medication.
Over 99.5% of patients reported no side effects, and none were considered serious adverse events.

Principal Investigators

Michael J. Brennan, MD

Chief Medical Officer
The Pain Center of Fairfield
Fairfield, CT

Senior Attending Physician
Department of Medicine Bridgeport Hospital
Bridgeport, CT

Associate Director
Chronic Pain & Recovery Program Silver Hill Hospital
New Canaan, CT

Jeffrey Gudin, MD

Director, Pain and Palliative Care
Englewood Hospital and Medical Center
New York, NY

Clinical Instructor, Anesthesiology
Icahn School of Medicine at Mount Sinai
New York, NY

Study Objective

To evaluate patient perceptions of pain treatment with the use of topical formulations alone or in combination with neuropathic supplements via a patient-reported survey.

OPERA Outcomes

OPERA study participants using a topical analgesic formulation for pain are reporting positive results. Statistically significant and positive interim OPERA results continue to be presented at important conferences, including the 4th Annual International Conference on Opioids at Harvard Medical School, among others.

Interim data presented from over 400 enrolled patients included the following positive key findings:

Reduced pain severity for patients with neuropathic and musculoskeletal pain

Reduced pain interference with general activity, mood, sleep, and life enjoyment

Reduced number of primary pain complaints for arthritis, neuropathy, or radiculopathy

Reduced use of over-the-counter medications, anti-inflammatory medications, and opioid analgesics

95% of patients were satisfied with the topical analgesic, and the topical analgesics were safe and well-tolerated.

OPERA Conference Highlights

MORE OPERA CONFERENCES